New
HealthMore in Health→
New Tumor Map Identifies High-Risk B-Cell Lymphoma Standard Therapy May Miss
Key Takeaways
- Researchers combined genetic and proteomic analyses to identify aggressive DLBCL subtypes.
- Standard R-CHOP therapy fails in over one-third of DLBCL patients due to molecular heterogeneity.
- New tumor map can flag high-risk patients who may need alternative treatments like CAR T-cell therapy.
- Experimental lab work identified potential therapeutic targets for aggressive subtypes.
DE
DT Editorial Team··via medicalxpress.com